BPC-157 vs Insulin
Overview
BPC-157 is primarily a healing & recovery peptide, while Insulin is used for weight management & metabolic.
This page compares BPC-157 and Insulin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| BPC-157 | Insulin | |
|---|---|---|
| Category | Healing & Recovery | Weight Management & Metabolic |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | FDA approved |
| Typical dosage | 250-500 mcg | Highly individualized; type 1 diabetes basal-bolus regimens typically require 0.5–1.0 units/kg/day total; type 2 diabetes is often initiated with basal insulin at 10 units or 0.1–0.2 units/kg/day, titrated to individual glycemic targets |
| Frequency | daily | Once daily (long-acting basal analogs) to four or more times daily (basal-bolus or continuous subcutaneous insulin infusion); prandial doses given 0–15 minutes before meals for rapid-acting analogs or 30 minutes before meals for regular human insulin |
| Reported benefits | Accelerated wound healing, tendon and ligament repair, gut health improvement, reduced inflammation, neuroprotective effects | Glycemic control, prevention of diabetic ketoacidosis, reduction of microvascular complications (retinopathy, nephropathy, neuropathy), life-sustaining therapy in type 1 diabetes, HbA1c reduction in type 2 diabetes |
| Reported side effects | Generally well-tolerated. Rare: injection site reactions, mild fatigue | Hypoglycemia, weight gain, injection-site lipohypertrophy, rare hypersensitivity reactions, peripheral edema at initiation |
Key differences
Primary use. BPC-157 is categorised under Healing & Recovery, while Insulin falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. BPC-157: not FDA-approved; compounding permitted with a prescription as of April 2026. Insulin: FDA-approved.
Dosing. BPC-157 is typically dosed at 250-500 mcg (daily). Insulin is typically dosed at Highly individualized; type 1 diabetes basal-bolus regimens typically require 0.5–1.0 units/kg/day total; type 2 diabetes is often initiated with basal insulin at 10 units or 0.1–0.2 units/kg/day, titrated to individual glycemic targets (Once daily (long-acting basal analogs) to four or more times daily (basal-bolus or continuous subcutaneous insulin infusion); prandial doses given 0–15 minutes before meals for rapid-acting analogs or 30 minutes before meals for regular human insulin).
Can you stack them?
Some protocols combine peptides, but stacking BPC-157 and Insulin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between BPC-157 and Insulin?
- BPC-157 is primarily a healing & recovery peptide, while Insulin is used for weight management & metabolic. BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Insulin is FDA-approved for one or more indications.
- What is BPC-157 used for?
- Healing & recovery, gut health.
- What is Insulin used for?
- The foundational peptide hormone for glycemic management in type 1 and type 2 diabetes mellitus.
- Can you take BPC-157 and Insulin together?
- Some users combine peptides within a single protocol, but stacking BPC-157 and Insulin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is BPC-157 or Insulin FDA-approved?
- BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026). Insulin is FDA-approved for one or more indications.